SLE患者启用阿尼鲁单抗的真实世界特征与早期应答:REVEAL研究中期分析
REVEAL是一项在意大利25个风湿科中心开展的前瞻性观察研究,中期分析纳入236例首次启用阿尼鲁单抗的SLE患者。6个月时140例可评估患者中26%达到缓解、57%达到LLDAS5、66%达到LLDAS,支持其真实世界临床获益与快速起效。
要点
- 6个月时26%达缓解、57%达LLDAS5、66%达LLDAS。
- 主要启用指征为黏膜皮肤(67%)和关节(49%)受累。
- 6个月内记录108例不良事件,其中83例(77%)为感染。
核心结论
- 本研究提供阿尼鲁单抗治疗SLE的首批大规模真实世界证据,支持其在常规诊疗中的临床获益与快速起效。
研究设计与样本
- REVEAL为5年、多中心、前瞻性观察研究,在意大利25个三级风湿科中心开展。
- 预设中期分析纳入截至2025年2月10日数据截止时启用阿尼鲁单抗的全部236例SLE患者,于基线及1、3、6个月采集数据。
- 纳入标准为年龄≥18岁、符合至少一套当时有效的SLE分类标准、疾病活动需要阿尼鲁单抗治疗且既往未使用过阿尼鲁单抗。
- 主要结局为6个月时达到缓解、LLDAS和LLDAS5的患者数,同时记录不良事件与严重不良事件。
主要发现
- 基线中位SLEDAI-2K为7(IQR 6-9),主要启用指征为黏膜皮肤受累157例(67%)和关节受累116例(49%)。
- 6个月时140例患者中37例(26%)达到缓解,80例(57%)达到LLDAS5,93例(66%)达到LLDAS;1例因医师整体评估数据缺失被排除出结局分析。
- 6个月随访期间记录108例不良事件,其中83例(77%)为感染;发生5例严重不良事件,导致6次住院。
关键数值与推荐
- LLDAS5为LLDAS的改良版本,泼尼松等效剂量阈值为≤5 mg/日。
临床怎么用
- 真实世界数据支持阿尼鲁单抗用于以黏膜皮肤和关节受累为主、疾病活动的SLE患者,并可在6个月内评估缓解与LLDAS达标情况。
- 治疗期间需关注感染事件,6个月随访中感染占不良事件的77%。
局限性
- 本文为预设中期分析,仅纳入前236例患者,6个月结局分析可评估者为140例。
- 研究为单国多中心观察性设计,无对照臂。
- 研究设计与实施未纳入有SLE亲身经历者参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anifrolumab is a type I interferon receptor antagonist approved for the treatment of systemic lupus erythematosus (SLE). However, real-world evidence on its use, especially from large, unselected cohorts, is scarce. The ongoing REVEAL study is designed to collect real-world data on anifrolumab use. The data reported here are the pre-specified 6-month interim analysis, which aims to provide a phenotypic characterisation of a large real-world cohort of patients with SLE initiating anifrolumab, and to evaluate early treatment response in routine clinical practice. METHODS: REVEAL is a 5-year, multicentre, prospective observational study conducted in 25 tertiary rheumatology centres across Italy. A pre-specified interim analysis was planned when the first 50 patients completed the first 6 months of follow-up; this analysis includes all patients who initiated anifrolumab by the data cutoff of Feb 10, 2025. Patients with SLE were consecutively enrolled on the day of their first infusion of anifrolumab, prescribed according to clinical judgement and Italian indications for use. Eligible patients were aged 18 years or older, had a clinical diagnosis of SLE fulfilling at least one set of established classification criteria valid at the time of diagnosis (1997 American College of Rheumatology [ACR], 2012 Systemic Lupus International Collaborating Clinics, or 2019 European Alliance of Associations for Rheumatology-ACR), had active disease warranting anifrolumab treatment (including compassionate use programmes), and were naive to anifrolumab. Data were collected at baseline and at 1 month, 3 months, and 6 months. The primary outcome was the number of patients reaching remission (defined according to the Definition of Remission in SLE criteria as a clinical SLEDAI-2K score of 0, physician global assessment score of <0·5 [on a 0-3 scale], with a prednisone-equivalent dose ≤5 mg per day, and stable antimalarials or immunosuppressants), Lupus Low Disease Activity State (LLDAS; defined as a SLEDAI-2K ≤4 [with no activity in major organ systems and no new disease activity], physician global assessment ≤1·0, and a prednisone-equivalent dose ≤7·5 mg per day), and LLDAS5 (a modified version of the LLDAS with a prednisone-equivalent dose ≤5 mg per day) at 6 months. Adverse and serious adverse events were also recorded. No people with lived experience of SLE were involved in designing or conducting the study. This study is registered with ClinicalTrials.gov (NCT07215754) and with the Italian Medicines Agency (Agenzia Italiana del Farmaco; ID number 247) and recruitment is ongoing. FINDINGS: Between May 25, 2023, and Feb 10, 2025, 236 patients were recruited and included in this interim analysis. Of these, 219 (93%) were female, 17 (7%) were male, 218 (92%) were White, and the median age was 46·9 years (IQR 36·0-53·6). At baseline, the median SLEDAI-2K was 7 (IQR 6-9), and the main indications for anifrolumab were mucocutaneous (157 [67%]) and articular (116 [49%]) involvement. At 6 months, 37 (26%) of 140 patients reached remission, 80 (57%) reached LLDAS5 and 93 (66%) reached LLDAS. One patient was excluded from the outcome analysis due to missing physician global assessment data. 108 adverse events were recorded during the 6-month follow-up period; of these, 83 (77%) were infections. Five serious adverse events occurred, resulting in six hospitalisations. INTERPRETATION: This study provides the first large-scale real-world evidence of anifrolumab use in patients with SLE, supporting its clinical benefit and rapid onset of action in routine care. FUNDING: None.
引用
- Tani C, Cardelli C, Moroni L, et al. Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study. Lancet Rheumatol. 2026. PMID: 41655581. doi:10.1016/S2665-9913(25)00316-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。